Advertisements


We are Sorry, This Page doesn't Exist


Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy Drug

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sarepta Therapeutics (SRPT) has good news for SRPT stock investors concerning its tr.....»»

Category: topSource: investorplaceDec 15th, 2019

First Week of May 2020 Options Trading For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsSep 24th, 2019

June 15th Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsApr 14th, 2018

November 2nd Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsSep 13th, 2018

Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?

Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dolla.....»»

Category: topSource: insidermonkeyDec 8th, 2018

April 18th Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsJan 14th, 2019

June 21st Options Now Available For Sarepta Therapeutics (SRPT)

Stock Options Channel.....»»

Category: topSource: redinewsFeb 1st, 2019

Sarepta"s stock is up 11% on positive data from clinical trial for Duchenne treatment

Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the co.....»»

Category: topSource: marketwatchMay 18th, 2021

: Sarepta stock plunges more than 50% after mixed results from drug study

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study......»»

Category: topSource: marketwatchJan 7th, 2021

In One Chart: Why an IPO ‘meltup’ could signal future trouble for the stock market

A red-hot reception for initial public offerings may offer another sign of froth in a rallying stock market, according to one measure......»»

Category: topSource: marketwatchDec 18th, 2020

Do Hedge Funds Love Sarepta Therapeutics Inc (SRPT)?

Coronavirus is probably the #1 concern in investors’ minds right now. It should be. On February 27th we published this article and pr.....»»

Category: topSource: insidermonkeyMar 11th, 2020

Sarepta Therapeutics Enters Oversold Territory (SRPT)

Dividend Channel.....»»

Category: topSource: redinewsFeb 27th, 2020

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: Latest Ratings for SRPT.....»»

Category: blogSource: benzingaDec 24th, 2019

Benzinga Pro"s Top 5 Stocks To Watch For Mon., Dec. 23, 2019: SRPT, ROK, CNSL, DPW, XFOR

Benzinga Pro's Stocks To Watch For Monday Sarepta Therapeutics (SRPT) - Shares were up about 9% Monday morning following news of a partnership with Roche (RRHBY) for its investigational read more.....»»

Category: blogSource: benzingaDec 23rd, 2019

In an about face, FDA approves Sarepta"s 2nd Duchenne drug

The FDA unexpectedly reversed course Thursday, approving the second treatment developed by Sarepta Therapeutics for the rare disease Duchenne muscular dystrophy just a few months after rejecting the drug.  Sarepta (Nasdaq: SRPT) announced Thursday even.....»»

Category: topSource: bizjournalsDec 12th, 2019

Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug

Sarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Admin.....»»

Category: topSource: marketwatchDec 12th, 2019

Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report?

Zacks.....»»

Category: topSource: redinewsDec 9th, 2019

Did Hedge Funds Drop The Ball On Sarepta Therapeutics Inc (SRPT) ?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why.....»»

Category: topSource: insidermonkeyDec 4th, 2019

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q3 2019 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaNov 8th, 2019

In One Chart: A surging stock market belies the biggest disagreement between CEOs and consumers about the U.S. economy on record

The stock market is in full flight Thursday, with all three main U.S. benchmarks poised to end at their highest levels ever, but those glorious gains come amid an uneasy gap in what consumers and C-suiters think about future of the U.S. economy......»»

Category: topSource: marketwatchNov 7th, 2019